Accuray is highlighting clinical results that suggest that early-stage breast cancer patients could have better survival outcomes when treated with accelerated partial breast irradiation (APBI) using the company's CyberKnife radiotherapy platform.
The modeling study, published in Frontiers in Oncology, found that the survival rate in this population could be better with CyberKnife APBI compared to other treatment approaches such as volumetric-modulated arc therapy, three-dimensional conformal radiation therapy ABPI, and high-dose-rate brachytherapy.
A team led by Dr. Jean-Philippe Pignol, PhD, Accuray's chief medical and technology officer, explored the risk of early-stage breast cancer patients developing radiation-induced secondary lung cancer from radiotherapy and whether particular radiotherapy techniques were less risky than others in this regard. The study included data from the Surveillance, Epidemiology, and End Results Program (SEER) from 1988 to 2012 and 765,697 nonmetastatic breast cancers. Of these, 49.8% were diagnosed in women who then received radiotherapy.
The investigators found that APBI delivered in one to five sessions reduced the risk of mortality from radiation-induced secondary lung cancer by more than 85%, Accuray said.
